Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States

BACKGROUND: Warfarin has a long history of use to reduce the risk of stroke in patients with atrial fibrillation (AF), but it requires frequent laboratory monitoring to maintain international normalized ratio levels in the therapeutic range. Dabigatran, a novel oral anticoagulant (OAC), has demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Rahul, Fu, An-Chen, Lim, Jonathan, Wang, Cheng, Elder, Jessica, Sander, Stephen D., Tan, Hiangkiat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398022/
https://www.ncbi.nlm.nih.gov/pubmed/29290177
http://dx.doi.org/10.18553/jmcp.2018.24.1.73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398022/
https://www.ncbi.nlm.nih.gov/pubmed/29290177
http://dx.doi.org/10.18553/jmcp.2018.24.1.73

Ejemplares similares